APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Disease: Memory impairment ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. 30050407 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Importantly, APP/PS1/δ<sup>D910A</sup> mice exhibited no spatial learning or memory deficits. 31363064 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Increased ILK expression of dentate gyrus (DG) rescued the hippocampus-dependent neurogenesis and memory deficits in APP/PS1 mice. 29787769 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Increase in presenilin 1 (PS1) levels in senescence-accelerated mice (SAMP8) may indirectly impair memory by affecting amyloid precursor protein (APP) processing. 19181896 2009
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we confirmed that four weeks' treatment of exendin-4 could rescue memory deficits and neuropathological changes in APP/PS1 mice. 29223528 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 GeneticVariation phenotype BEFREE BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. 17258906 2007
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE First, silibinin and silymarin administration could alleviate memory deficits and reduce the amyloid plaque burden in the brain of APP/PS1 mice in comparison with controls. 31236617 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Restraint/isolation stress induced significant depressive-like behaviors in APP/PS1 mice at 4 months of age and memory impairment at 10 months of age, while 6 months of icariin administration relieved the memory damage. 31001073 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE In the present study, we evaluated the therapeutic effect of WJ-MSC transplantation on the neuropathology and memory deficits in amyloid precursor protein (APP) and presenilin-1 (PS1) double-transgenic mice and discussed the mechanism. 26188488 2016
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects. 28065587 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The studied dendrimers did not reverse memory impairment in APP/PS1 mice following chronic administration; moreover, cationic G4mOS caused cognitive decline in nontransgenic mice. 24004423 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Thus far, the one manipulation found to mitigate the learning and memory deficits in APP transgenic mice is immunotherapy for A beta, either using active or passive immunization against the peptide. 12737527 2003
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE SNX8 Enhances Non-amyloidogenic APP Trafficking and Attenuates Aβ Accumulation and Memory Deficits in an AD Mouse. 31551717 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE We show that inhibition of APP cleavage by β-secretase rescues synaptic/memory deficits in a mouse model of FDD. 22170863 2012
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Second, we used an APPswe/PS1E9 (APP/PS1) double transgenic mice to evaluate the amelioration ability of simvastatin against the memory impairment in vivo. 28528185 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Behavioral tests further confirmed PTS' potential of overcoming memory deficits in APP/PS1 mice (AD model). 31737188 2019
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Although Abeta derived from the Abeta precursor protein (beta-APP) is believed to play a central etiological role in AD, it is not clear whether soluble and/or fibrillar forms are responsible for the memory deficit. 11724968 2001
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE An efficacy test carried out in APP/PS1 transgenic mice showed a reduction of memory deficit in mice chronically treated with PGZ-NPs. 30271148 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we showed that systemic treatment of APP and presenilin 1 (PS1) transgenic mice, a robust Alzheimer's disease (AD) mouse model, with indirubin-3'-monoxime (IMX; 20mg/kg; 3 times weekly), for as little as 2months, significantly attenuated spatial memory deficits. 20381617 2010
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here, we show that xanthoceraside at doses of 0.08 and 0.32 mg/kg/d for 6 months significantly improved learning and memory impairment in APP transgenic mice assessed by the Y maze and novel object recognition tests. 24810883 2014
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE In contrast, C57 APP/PS1 and SAMP8 wild type mice were inconspicuous in all of these tasks and properties except C57 APP/PS1 mice which showed motor memory impairment in the shuttle box task at 9 months old. 24095271 2013
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Xanthoceraside administration alleviated learning-memory deficits and increased the LTP in APP/PS1 transgenic mice. 29124300 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here we aimed to determine whether chronic treatment with the α(2)-adrenoceptor antagonist fluparoxan, that enhances noradrenaline release, can prevent the onset of Alzheimer's-like pathology and memory deficits in APP/PS1 transgenic mice (TASTPM). 20850464 2011
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE In addition, age-dependent spatial memory deficits in APP/PS1 mice were reversed in TRPM2(-/-)/APP/PS1 mice. 26558786 2015
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE MCH improved memory impairment in both models and reduced soluble amyloid beta in the cerebral cortex of APP/PS1 transgenic mice. 31183806 2019